TG Therapeutics Inc
TGTX30.300USD
-1.940-6.02%
Close 11/10, 16:00（ET）Quotes delayed by 15 min
4.70BMarket Cap
10.51P/E TTM
More Details of TG Therapeutics Inc Company
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
TG Therapeutics Inc Info
Ticker SymbolTGTX
Company nameTG Therapeutics Inc
IPO dateDec 14, 1995
CEOMr. Michael S. Weiss, J.D.
Number of employees338
Security typeOrdinary Share
Fiscal year-endDec 14
Address3020 Carrington Mill Blvd., Suite 475
CityMORRISVILLE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code27560-5435
Phone18775758489
Websitehttps://www.tgtherapeutics.com/
Ticker SymbolTGTX
IPO dateDec 14, 1995
CEOMr. Michael S. Weiss, J.D.
Company Executives of TG Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
9.16M
-33.77%
Mr. Sean A. Power
Mr. Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
600.61K
-19.72%
Mr. Kenneth (Ken) Hoberman
Mr. Kenneth (Ken) Hoberman
Independent Director
Independent Director
279.65K
+5.56%
Dr. Yann Echelard
Dr. Yann Echelard
Independent Director
Independent Director
228.82K
+2.11%
Mr. Laurence Neil (Larry) Charney, CPA
Mr. Laurence Neil (Larry) Charney, CPA
Lead Independent Director
Lead Independent Director
222.89K
+10.63%
Mr. Daniel Hume, J.D.
Mr. Daniel Hume, J.D.
Independent Director
Independent Director
192.75K
+8.27%
Dr. Sagar Lonial
Dr. Sagar Lonial
Independent Director
Independent Director
94.06K
-18.15%
Name
Name/Position
Position
Shareholding
Change
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
9.16M
-33.77%
Mr. Sean A. Power
Mr. Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
600.61K
-19.72%
Mr. Kenneth (Ken) Hoberman
Mr. Kenneth (Ken) Hoberman
Independent Director
Independent Director
279.65K
+5.56%
Dr. Yann Echelard
Dr. Yann Echelard
Independent Director
Independent Director
228.82K
+2.11%
Mr. Laurence Neil (Larry) Charney, CPA
Mr. Laurence Neil (Larry) Charney, CPA
Lead Independent Director
Lead Independent Director
222.89K
+10.63%
Mr. Daniel Hume, J.D.
Mr. Daniel Hume, J.D.
Independent Director
Independent Director
192.75K
+8.27%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q1
FY2024
By BusinessUSD
Name
Revenue
Proportion
Total product revenue, net
119.66M
99.01%
Royalty Revenue
605.00K
0.50%
Other Revenue
558.00K
0.46%
License Revenue
38.00K
0.03%
Milestone Revenue
0.00
0.00%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Total product revenue, net
119.66M
99.01%
Royalty Revenue
605.00K
0.50%
Other Revenue
558.00K
0.46%
License Revenue
38.00K
0.03%
Milestone Revenue
0.00
0.00%
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.05%
The Vanguard Group, Inc.
9.75%
Weiss (Michael S)
5.77%
State Street Investment Management (US)
5.10%
Geode Capital Management, L.L.C.
2.20%
Other
65.13%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.05%
The Vanguard Group, Inc.
9.75%
Weiss (Michael S)
5.77%
State Street Investment Management (US)
5.10%
Geode Capital Management, L.L.C.
2.20%
Other
65.13%
Shareholder Types
Shareholders
Proportion
Investment Advisor
36.27%
Investment Advisor/Hedge Fund
16.92%
Individual Investor
9.73%
Hedge Fund
5.99%
Research Firm
3.02%
Pension Fund
1.31%
Bank and Trust
0.39%
Family Office
0.13%
Sovereign Wealth Fund
0.06%
Other
26.18%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
698
101.46M
63.91%
-17.24M
2025Q2
693
115.94M
73.03%
-21.56M
2025Q1
704
116.82M
73.80%
-25.76M
2024Q4
657
113.87M
72.65%
-36.14M
2024Q3
598
117.83M
76.11%
-20.28M
2024Q2
544
109.58M
70.90%
-28.91M
2024Q1
535
105.41M
68.45%
-29.01M
2023Q4
542
104.64M
69.13%
-36.73M
2023Q3
552
104.67M
69.33%
-30.54M
2023Q2
543
102.45M
68.58%
-35.33M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
19.13M
12.06%
-84.56K
-0.44%
Jun 30, 2025
The Vanguard Group, Inc.
15.77M
9.94%
+203.00K
+1.30%
Jun 30, 2025
Weiss (Michael S)
13.82M
8.71%
--
--
Apr 14, 2025
State Street Investment Management (US)
7.62M
4.8%
+184.34K
+2.48%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.49M
2.2%
+207.89K
+6.33%
Jun 30, 2025
ClearBridge Investments, LLC
3.05M
1.92%
+408.10K
+15.43%
Jun 30, 2025
Soleus Capital Management, L.P.
2.24M
1.41%
-602.77K
-21.17%
Jun 30, 2025
Pictet Asset Management Ltd.
1.91M
1.2%
-489.69K
-20.43%
Jun 30, 2025
Hood River Capital Management LLC
1.57M
0.99%
+11.02K
+0.71%
Jun 30, 2025
Fidelity Management & Research Company LLC
1.55M
0.98%
-189.89K
-10.90%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Invesco S&P SmallCap Health Care ETF
3.12%
SPDR S&P Biotech ETF
1.97%
Virtus LifeSci Biotech Products ETF
1.61%
Invesco S&P SmallCap 600 Pure Growth ETF
1.53%
Invesco S&P SmallCap Momentum ETF
1.34%
Direxion Daily S&P Biotech Bull 3X Shares
1.03%
SPDR S&P 600 Small Cap Growth ETF
0.66%
Vanguard S&P Small-Cap 600 Growth Index Fund
0.66%
VanEck Social Sentiment ETF
0.63%
iShares S&P Small-Cap 600 Growth ETF
0.62%
View more
Invesco S&P SmallCap Health Care ETF
Proportion3.12%
SPDR S&P Biotech ETF
Proportion1.97%
Virtus LifeSci Biotech Products ETF
Proportion1.61%
Invesco S&P SmallCap 600 Pure Growth ETF
Proportion1.53%
Invesco S&P SmallCap Momentum ETF
Proportion1.34%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion1.03%
SPDR S&P 600 Small Cap Growth ETF
Proportion0.66%
Vanguard S&P Small-Cap 600 Growth Index Fund
Proportion0.66%
VanEck Social Sentiment ETF
Proportion0.63%
iShares S&P Small-Cap 600 Growth ETF
Proportion0.62%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
